Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

INTRODUCTION: Daratumumab, a human IgG monoclonal antibody targeting CD38, has demonstrated activity as monotherapy and in combination with standard-of-care regimens in multiple myeloma. Population pharmacokinetic analyses were conducted to determine the pharmacokinetics of intravenous daratumumab i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xu Steven, Dimopoulos, Meletios A., Sonneveld, Pieter, Ho, P. Joy, Belch, Andrew, Leiba, Merav, Capra, Marcelo, Gomez, David, Medvedova, Eva, Iida, Shinsuke, Min, Chang-Ki, Schecter, Jordan, Jansson, Richard, Zhang, Liping, Sun, Yu-Nien, Clemens, Pamela L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223994/
https://www.ncbi.nlm.nih.gov/pubmed/30374808
http://dx.doi.org/10.1007/s12325-018-0815-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223994/
https://www.ncbi.nlm.nih.gov/pubmed/30374808
http://dx.doi.org/10.1007/s12325-018-0815-9

Ejemplares similares